Demand for immunity products to be sustained long-term says SIRIO
Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.
Worldwide demand for immunity products has accelerated in recent months due to coronavirus. This trend is likely to deliver a 'new norm' of higher growth, says SIRIO Europe (Ayanda) — the European headquarters of the SIRIO Group, a global nutraceutical contract development, innovation and manufacturing organization (CDiMO).
Europe has already seen a significant spike in the demand for immunity products across the main economies. Recent weekly data from Euromonitor show an increased purchasing of vitamin C and multivitamins by consumers, with unusual levels of stockouts present throughout Europe.
During lockdowns, production and supply chains have been fairly robust, but there have still been large stock shortages. This is surprising given that we are approaching summer, which is not traditionally a peak period for these products. Anticipating a surge, Dr Dominique Baum, Managing Director at SIRIO Europe (Ayanda), advised that the company has secured a "very large inventory of ingredients to ensure continuity of supply" for all its customers.
In addition, confinement regulations have left consumers with reduced exposure to sunlight which, in turn, has increased sales of nutraceuticals containing vitamin D or other ingredients that compensate for the lack of natural daylight.
Also proving popular among consumers are products that strengthen their respiratory and cardiovascular systems, with omega-3 fatty acids and antioxidants (that may protect against oxidative stress). The company suggests the long-term cumulative effect will be continued growth in health-boosting and immune-boosting supplements, adding a further driver to an already expanding nutraceuticals class.
“The lasting impact of the virus will see a further acceleration of an already popular product class and, in the next few years, we will likely see many new innovative immune formulations delivered via softgels and gummies. Consumers will be looking for new ways to potentially boost health and immunity with combination products, and we anticipate those products with multiple actives are likely to be increasingly popular. It’s a difficult time for society, but it could lead to further improvements with an increased consumer focus on wellbeing,” said Dr Baum.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance